ORIC Pharmaceuticals Q4 loss narrows

ORIC Pharmaceuticals

23/02/2026 21:18

Overview

Oncology firm's Q4 net loss narrowed to $30.5 mln from $36.3 mln last year

Company raised $264 mln, extending cash runway into 2H 2028

Significant clinical advancements in rinzimetostat and enozertinib reported

Outlook

ORIC expects rinzimetostat dose optimization data in Q1 2026

Company plans to initiate Phase 3 trial for rinzimetostat in 1H 2026

ORIC anticipates enozertinib monotherapy data in 2H 2026

Result Drivers

R&D EXPENSES - Reduced to $25.9 mln from $32 mln due to lower rinzimetostat drug manufacturing costs and lower costs from discontinued programs

CASH RUNWAY EXTENSION - Company raised $264 mln, extending cash runway into 2H 2028

Company press release: ID:nGNX4wfBSH

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Net Income
-$30.51 mln
Q4 Income from Operations
-$34.55 mln
Q4 Operating Expenses
$34.55 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Oric Pharmaceuticals Inc is $22.00, about 98% above its February 20 closing price of $11.11

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)